BIOMAT Database Logo BIOMAT Database Logo

Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group. 1999

P J Meunier, and E Vignot, and P Garnero, and E Confavreux, and E Paris, and S Liu-Leage, and S Sarkar, and T Liu, and M Wong, and M W Draper
Service de Rhumatologie et de Pathologie Osseuse, Hôpital Edouard Herriot, Lyon, France.

Raloxifene, a selective estrogen receptor modulator (SERM), has been shown to improved bone mineral density (BMD) and serum lipid profiles in healthy postmenopausal women. The objective of this study was to examine the effects of raloxifene on BMD, biochemical markers of bone metabolism and serum lipids in postmenopausal women with low bone density or osteoporosis. This Phase II, multicenter, 24-month, double-masked study assessed the efficacy and safety of raloxifene in 129 postmenopausal women (mean age +/- SD: 60.2 +/- 6.7 years) with osteoporosis or low bone density (baseline mean lumbar spine BMD T-score: -2.8). Women were randomly assigned to one of three treatment groups: placebo, 60 mg/day raloxifene-HCl (RLX 60) or 150 mg/day raloxifene-HCL (RLX 150) and concomitantly received 1000 mg/day calcium and 300 U/day vitamin D3. At 24 months, BMD was significantly increased in the lumbar spine (+3.2%), femoral neck (+2.1%), trochanter (+2.7%) and total hip (+1.6%) in the RLX 60 group compared with the placebo group (p < 0.05). The RLX 150 group had increases in BMD similar to those observed with RLX 60. A greater percentage of raloxifene-treated patients, compared with those receiving placebo, had increased BMD (p < 0.05). Serum bone-specific alkaline phosphatase activity, serum osteocalcin, and urinary type I collagen:creatinine ratio were significantly decreased in the RLX-treated groups, compared with the placebo group (p < 0.01). RLX 60 treatment significantly decreased serum levels of triglycerides, and total- and LDL-cholesterol levels (p < 0.01). The rates of patient discontinuation and adverse events were not significantly different among groups. In this study, raloxifene increased bone density, decreased bone turnover, and improved the serum lipid profile with minimal adverse events, and may be a safe and effective treatment for postmenopausal women with osteoporosis or low bone density.

UI MeSH Term Description Entries
D008078 Cholesterol, LDL Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol. LDL Cholesterol,Cholesteryl Linoleate, LDL,LDL Cholesteryl Linoleate,Low Density Lipoprotein Cholesterol,beta-Lipoprotein Cholesterol,Cholesterol, beta-Lipoprotein,beta Lipoprotein Cholesterol
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D002762 Cholecalciferol Derivative of 7-dehydroxycholesterol formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. It differs from ERGOCALCIFEROL in having a single bond between C22 and C23 and lacking a methyl group at C24. Vitamin D 3,(3 beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol,Calciol,Cholecalciferols,Vitamin D3
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004965 Estrogen Antagonists Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds. Estradiol Antagonists,Antagonists, Estradiol,Antagonists, Estrogen
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

P J Meunier, and E Vignot, and P Garnero, and E Confavreux, and E Paris, and S Liu-Leage, and S Sarkar, and T Liu, and M Wong, and M W Draper
Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia).
January 2014, Clinical interventions in aging,
P J Meunier, and E Vignot, and P Garnero, and E Confavreux, and E Paris, and S Liu-Leage, and S Sarkar, and T Liu, and M Wong, and M W Draper
Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis.
January 2014, Archives of osteoporosis,
P J Meunier, and E Vignot, and P Garnero, and E Confavreux, and E Paris, and S Liu-Leage, and S Sarkar, and T Liu, and M Wong, and M W Draper
[Treatment of postmenopausal osteoporosis with raloxifene].
January 2000, Bratislavske lekarske listy,
P J Meunier, and E Vignot, and P Garnero, and E Confavreux, and E Paris, and S Liu-Leage, and S Sarkar, and T Liu, and M Wong, and M W Draper
Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
March 2008, Current medical research and opinion,
P J Meunier, and E Vignot, and P Garnero, and E Confavreux, and E Paris, and S Liu-Leage, and S Sarkar, and T Liu, and M Wong, and M W Draper
Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women.
January 2021, Frontiers in pharmacology,
P J Meunier, and E Vignot, and P Garnero, and E Confavreux, and E Paris, and S Liu-Leage, and S Sarkar, and T Liu, and M Wong, and M W Draper
Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene and/or alfacalcidol in postmenopausal Japanese women.
March 2010, Journal of bone and mineral metabolism,
P J Meunier, and E Vignot, and P Garnero, and E Confavreux, and E Paris, and S Liu-Leage, and S Sarkar, and T Liu, and M Wong, and M W Draper
Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis.
January 2014, International journal of clinical and experimental pathology,
P J Meunier, and E Vignot, and P Garnero, and E Confavreux, and E Paris, and S Liu-Leage, and S Sarkar, and T Liu, and M Wong, and M W Draper
[Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
February 2004, Zhonghua yi xue za zhi,
P J Meunier, and E Vignot, and P Garnero, and E Confavreux, and E Paris, and S Liu-Leage, and S Sarkar, and T Liu, and M Wong, and M W Draper
Raloxifene reduces fractures in postmenopausal women with osteoporosis.
February 2006, Clinical orthopaedics and related research,
P J Meunier, and E Vignot, and P Garnero, and E Confavreux, and E Paris, and S Liu-Leage, and S Sarkar, and T Liu, and M Wong, and M W Draper
Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density.
August 2011, Menopause (New York, N.Y.),
Copied contents to your clipboard!